U.S. Department of Health & Human Services
National Institutes of Health
NCATS
This repository is under review for potential modification in compliance with Administration directives.
Dismiss
Return Home
Inxight
Drugs
Search Substances
Home
Browse Drugs
US Approved Drugs
Marketed Drugs
Investigational Drugs
All Substances
Search
Structure Search
Sequence Search
Downloads
About
Search Substances
MARZEPTACOG ALFA (ACTIVATED)
J5LT149M79
Investigational
General
Record Details
Names
7
Classification
4
Identifiers
6
Subunits
2
Disulfide Links
12
Glycosylation
5
Active Moiety
1
Modifications
2
Characteristic Attributes
2
MARZEPTACOG ALFA (ACTIVATED)
J5LT149M79
Investigational
General
Approval Year
Unknown
149,124
Record Details
Substance Class
Protein
Protein Sub Type
Sequence Type
COMPLETE
Record UNII
J5LT149M79
Record Status
Validated (UNII)
Record Version
17
16
15
14
13
12
11
10
9
8
7
6
5
4
3
2
1
Names
7
Show
5
20
100
All
entries
Name
Type
Language
Name
Type
Language
BLOOD-COAGULATION FACTOR VIIA (128-ASPARAGINE,129-ALANINE,286-ARGININE,298-GLUTAMINE) (SYNTHETIC HUMAN)
Preferred Name
English
MARZEPTACOG ALFA (ACTIVATED)
Official Name
English
CB-813
Common Name
English
Marzeptacog alfa (activated) [WHO-DD]
Common Name
English
PF-05280602
Code
English
Showing 1 to 5 of 7 entries
Previous
1
2
Next
Classification
4
Show
5
20
100
All
entries
Classification Tree
Code System
Code
Classification Tree
Code System
Code
Designated
ORPHAN DRUG
Designated
Treatment of Bleeding Episodes in Patients with Hemophilia A or B, Including those with Inhibitors
FDA ORPHAN DRUG
820721
Designated
ORPHAN DRUG
Designated
Treatment of Factor VII Deficiency
FDA ORPHAN DRUG
837721
Designated
ORPHAN DRUG
Designated
Routine prophylaxis to prevent bleeding episodes in patients with hemophilia A and B patients with inhibitors
FDA ORPHAN DRUG
377612
Positive
EU ORPHAN DRUG
Positive
Treatment of haemophilia B
EU-Orphan Drug
EU/3/19/2151
Showing 1 to 4 of 4 entries
Previous
1
Next
Identifiers
6
Show
5
20
100
All
entries
Code System
Code
Type
Description
Code System
Code
Type
Description
DRUG BANK
DB15278
PRIMARY
CAS
1600492-21-4
PRIMARY
NCI_THESAURUS
C170152
PRIMARY
INN
10157
PRIMARY
FDA UNII
J5LT149M79
PRIMARY
Showing 1 to 5 of 6 entries
Previous
1
2
Next
Subunits
2
Subunit 0
>SUBUNIT_0
Subunit 1
>SUBUNIT_1
Disulfide Links
12
Show
5
20
100
All
entries
From
To
From
To
1_7
1_12
1_26
1_42
1_110
2_135
1_158
1_177
1_188
1_216
Showing 1 to 5 of 12 entries
Previous
1
2
3
Next
Glycosylation
5
Show
5
20
100
All
entries
Glycosylation Link Type
Site
Glycosylation Link Type
Site
N
1_170
N
2_128
N
2_145
O
2_52
O
2_60
Showing 1 to 5 of 5 entries
Previous
1
Next
Active Moiety
1
Show
5
20
100
All
entries
Related Record
Type
Details
Related Record
Type
Details
J5LT149M79
MARZEPTACOG ALFA (ACTIVATED)
ACTIVE MOIETY
Showing 1 to 1 of 1 entries
Previous
1
Next
Modifications
2
Structural Modifications
Show
5
20
100
All
entries
Modification Type
Location Site
Location Type
Residue Modified
Extent
Fragment Name
Fragment Approval
Modification Type
Location Site
Location Type
Residue Modified
Extent
Fragment Name
Fragment Approval
FRAGMENT
[2_63]
D
.BETA.-HYDROXY-L-ASPARTIC ACID, ERYTHRO-
GDV0MSK2SG
FRAGMENT
[2_6] [2_7] [2_14] [2_16] [2_19] [2_20] [2_25] [2_26] [2_29] [2_35]
E
.GAMMA.-CARBOXYGLUTAMIC ACID
16FQV4RZKL
Showing 1 to 2 of 2 entries
Previous
1
Next
Characteristic Attributes
2
Show
5
20
100
All
entries
Name
Property Type
Amount
Referenced Substance
Defining
Parameters
References
Name
Property Type
Amount
Referenced Substance
Defining
Parameters
References
MOL_WEIGHT:NUMBER(CALCULATED)
CHEMICAL
ESTIMATED 43800 Da (average)
Molecular Formula
CHEMICAL
ESTIMATED
C1921H2994N554O568S27
Showing 1 to 2 of 2 entries
Previous
1
Next
